Linked Life Data

3334548

Source:http://linkedlifedata.com/resource/pubmed/id/3334548

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:dateCreated
1989-10-3
pubmed:abstractText
Although patients with Alzheimer disease have a well-demonstrated deficit in cortical cholinergic markers, treatments designed to enhance cholinergic activity in the central nervous system have not achieved the clinical success of dopamine replacement for Parkinson disease. A brief review of recent clinical reports and some developments in the neurosciences suggests that it may be premature, however, to abandon the search for benefit from cholinergic enhancement therapy in Alzheimer disease.
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:issn
0736-3583
pubmed:author
pubmed:issnType
Print
pubmed:volume
52
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
34-7
pubmed:dateRevised
2005-11-16
pubmed:meshHeading
pubmed:year
1987
pubmed:articleTitle
Update on cholinergic enhancement therapy for Alzheimer disease.
pubmed:affiliation
Department of Psychiatry and Biobehavioral Sciences, University of California, Los Angeles.
pubmed:publicationType
Journal Article, Review